SAM
SPRY icon

Shell Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Shell Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-65,322
Closed -$438K – 1280
2023
Q2 		$438K Buy
+65,322
New +$436K 0.02% 630

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Shell Asset Management's SPRY Position: Q3 2023 in Review

Shell Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2023, closing a stake of 65,322 shares — an estimated $438K sold.

Shell Asset Management first reported a position in SPRY in Q2 2023 and held it in 1 quarter. The position peaked at $438K in Q2 2023. 97 funds tracked by Wall St. Rank hold SPRY as of Q3 2023.

  • Shell Asset Management reported no remaining ARS Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Shell Asset Management sold 65,322 ARS Pharmaceuticals shares in Q3 2023, an estimated $438K.
  • Shell Asset Management first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Shell Asset Management's ARS Pharmaceuticals position peaked at $438K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2023.

Based on Shell Asset Management's 13F filing for Q3 2023, filed 8 Nov 2023.